Vesalius Biocapital related stories
All articles and analysis
Euroscreen raises $17.8 mlnEuroscreen said Friday it raised 16 million euros (US$17.8 million) in a series B funding round. SFPI-FPIM and Fund+ co-led the round. Existing shareholders including Vesalius Biocapital II Partners, SRIW SA, BNP Paribas Fortis Private Equity, as well as new comer as Capricorn Health-Tech Fund NV also participated. Euroscreen, a drug development company, is backed by Vesalius Biocapital, SFPI-FPIM, SRIW, Fund+ and BNP Paribas Fortis Private Equity.
- Apitope raises $13.5 mln
Apitope said Tuesday it raised 12 million euros (US$13.5 million) in Series B financing led by new investor Wales Life Sciences Fund. Current investors Vesalius Biocapital, LRM, PMV and Wyvern also participated in the round. Cardiff, England-based Apitope is a drug discovery and development company.
- Omeicos Therapeutics attracts Series A funds
Berlin, Germany-based Omeicos Therapeutics, a biopharmaceutical company focused on preventing and treating cardiovascular diseases, has secured 6.2 million euros in Series A funding. The investors included Vesalius Biocapital, VC Fonds Technologie Berlin, Hightech Gruenderfonds and KfW Group.
- Promethera Biosciences nabs $31.4 Series C
Belgium-based Promethera Biosciences, a biotech firm that focuses on treating liver diseases, has closed its Series C round at $31.4 million. The investors included SFPI-FPIM, Vesalius Biocapital, Boehringer Ingelheim Venture Fund and SMS Investments.
- Voluntis raises $29 mln
Voluntis has completed a $29 million Series D financing round. The round was co-led by Bpifrance Large Venture and international venture capital firm Innovation Capital. Voluntis existing Series C investors, CapDecisif Management, CM-CIC Capital Innovation and Sham, also participated in the round.
- Vesalius Biocapital and Capricorn Venture Partners lead Series B round for TROD Medical
Medical device company TROD Medical NV/SA said Thursday that it has closed 4.75 million euros in Series B financing. Vesalius Biocapital and Capricorn Venture Partners co-led the round. Other investors included Gemma Frisius Fund, the spin-off fund of the University of Leuven and the Flemish investment firm PMV. As part of the financing, TROD Medical has relocated its headquarters to Leuven, Belgium. Also, TROD Medical has named Frank Bulens of Capricorn Venture Partners and Stéphane Verdood of Vesalius BioCapital to the company's board of directors.
- Slideshow: Will 2012 put European Biotech Back on the Map?
European life sciences fundraising and investments still haven't reached anywhere near the heady 2006 levels But news of Index Ventures most recent fundraising are sending vibes of optimism and hope for a revival of European biotech.